Down syndrome and Alzheimer's disease: Common pathways, common goals

Inhibition and impulsivity: behavioral and neural basis of response control

Bari, A., & Robbins, T. W. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.005 · Cited by 1,921

APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

Rovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,284

Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome

Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159

Endocytic Pathway Abnormalities Precede Amyloid β Deposition in Sporadic Alzheimer’s Disease and Down Syndrome

Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gomez-Isla, T., Hyman, B. T., & Nixon, R. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64538-5 · Cited by 776

Amyloid A4 Protein and Its Precursor in Down's Syndrome and Alzheimer's Disease

Rumble, B. A., Retallack, R. W., Hilbich, C., Simms, G., Multhaup, G., Martins, R. N., Hockey, A., Montgomery, P., Beyreuther, K. T., & Masters, C. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906013202203 · Cited by 656

Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation

Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584

A Prospective Study of Alzheimer Disease in Down Syndrome

Lai, F., & Williams, R. S. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520440031017 · Cited by 561

Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration

Salehi, A., Delcroix, J.-D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., Takimoto-Kimura, R., Kleschevnikov, A. M., Sambamurti, K., Chung, P. P., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.05.022 · Cited by 543

Cognitive deficits and associated neurological complications in individuals with Down's syndrome

Lott, I. T., & Dierssen, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70112-5 · Cited by 484

Informal Caregivers and Psychosocial Support: Analysis of European Dementia Policy documents

Tokovská, M., Nour, M. M., Sørensen, A. Ø., & Goth, U. S. (2021) · Journal of Public Health Research · doi:10.4081/jphr.2021.2416 · Cited by 30

Dysregulation of the Retromer Complex System in Down Syndrome

Curtis, M. E., Yu, D., & Praticò, D. (2020) · Annals of Neurology · doi:10.1002/ana.25752 · Cited by 29

Remote Exercise for Adults with Down Syndrome

Ptomey, L., Szabo, A., Willis, E. A., Greene, J., Danon, J., Washburn, R., Forsha, D., & Donnelly, J. (2018) · Translational Journal of The American College of Sports Medicine · doi:10.1249/tjx.0000000000000058 · Cited by 22

Basal forebrain cholinergic neurons are vulnerable in a mouse model of Down syndrome and their molecular fingerprint is rescued by maternal choline supplementation

Alldred, M. J., Pidikiti, H., Heguy, A., Roussos, P., & Ginsberg, S. D. (2023) · The FASEB Journal · doi:10.1096/fj.202202111rr · Cited by 21

Maternal choline supplementation protects against age-associated cholinergic and GABAergic basal forebrain neuron degeneration in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease

Gautier, M. K., Kelley, C. M., Lee, S. H., Alldred, M. J., McDaid, J., Mufson, E. J., Stutzmann, G. E., & Ginsberg, S. D. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106332 · Cited by 21

Dreaming of a New World Where Alzheimer’s Is a Treatable Disorder

Catania, M., Giaccone, G., Salmona, M., Tagliavini, F., & Fede, G. D. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00317 · Cited by 25

Neurogenesis and neuronal differentiation in the postnatal frontal cortex in Down syndrome

Utagawa, E. C., Moreno, D. G., Schafernak, K. T., Arva, N. C., Malek‐Ahmadi, M. H., Mufson, E. J., & Perez, S. E. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01385-w · Cited by 24

A Review of Biomarkers for Alzheimer’s Disease in Down Syndrome

Lee, N., Chien, Y., & Hwu, W. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0071-y · Cited by 23

The promotion of physical activity for the prevention of Alzheimer's disease in adults with Down Syndrome: Rationale and design for a 12 Month randomized trial

Ptomey, L. T., Szabo‐Reed, A. N., Martin, L. E., Mayo, M. S., Washburn, R. A., Gorczyca, A. M., Lepping, R. J., Lee, P., Forsha, D. E., Sherman, J. R., et al. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100607 · Cited by 22

Serum neurofilament light chain as a surrogate of cognitive decline in sporadic and familial frontotemporal dementia

Silva‐Spínola, A., Lima, M., Leitão, M. J., Durães, J., Tábuas‐Pereira, M., Almeida, M. R., Santana, I. J., & Baldeiras, I. (2021) · European Journal of Neurology · doi:10.1111/ene.15058 · Cited by 22

Small Neuron-Derived Extracellular Vesicles from Individuals with Down Syndrome Propagate Tau Pathology in the Wildtype Mouse Brain

Ledreux, A., Thomas, S., Hamlett, E. D., Trautman, C. W., Gilmore, A., Hager, E. R., Paredes, D., Margittai, M., Fortea, J., & Granholm, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173931 · Cited by 23

Common genetic signatures of Alzheimer’s disease in Down Syndrome

Sharma, A., Chunduri, A., Gopu, A., Shatrowsky, C., Crusio, W. E., & Delprato, A. (2020) · F1000Research · doi:10.12688/f1000research.27096.1 · Cited by 22

Mitochondrial Extracellular Vesicles in CNS Disorders: New Frontiers in Understanding the Neurological Disorders of the Brain

Nakamya, M. F., Sil, S., Buch, S. J., & Hakami, R. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.840364 · Cited by 22

Alzheimer’s disease is an inherent, natural part of human brain aging: an integrated perspective

Ferrer, I. (2022) · Free Neuropathology · doi:10.17879/freeneuropathology-2022-3806 · Cited by 25

Exosome release and cargo in Down syndrome

Hamlett, E. D., LaRosa, A., Mufson, E. J., Fortea, J., Ledreux, A., & Granholm, A. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22712 · Cited by 21

Getting Into the Brain: The Intranasal Approach to Enhance the Delivery of Nerve Growth Factor and Its Painless Derivative in Alzheimer’s Disease and Down Syndrome

Capsoni, S., & Cattaneo, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.773347 · Cited by 21

Down syndrome biobank consortium: a perspective

Aldecoa, I., Barroeta, I., Carroll, S. L., Fortea, J., Gilmore, A., Ginsberg, S. D., Guzman, S. J., Hamlett, E. D., Head, E., Perez, S. E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13692 · Cited by 19

Blood biomarkers in Down syndrome: Facilitating Alzheimer's disease detection and monitoring

Petersen, M. E., Aguilar, L. F., Head, E., Montoliu‐Gaya, L., Strydom, A., Pape, S. E., Fortea, J., Ashton, N. J., Udeh‐Momoh, C. T., O’Bryant, S. E., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14364 · Cited by 20

Wnd/DLK Is a Critical Target of FMRP Responsible for Neurodevelopmental and Behavior Defects in the Drosophila Model of Fragile X Syndrome

Russo, A., & DiAntonio, A. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.001 · Cited by 25

The Effects of Resistance Training on Physical Fitness and Neuromotor-Cognitive Functions in Adults With Down Syndrome

Post, E. M., Kraemer, W. J., Kackley, M. L., Caldwell, L. K., Volek, J. S., Sanchez, B. N., Focht, B. C., Newton, R. U., Häkkinen, K., & Maresh, C. M. (2022) · Frontiers in Rehabilitation Sciences · doi:10.3389/fresc.2022.927629 · Cited by 19

The Role of Tau Pathology in Alzheimer’s Disease and Down Syndrome

Granholm, A., & Hamlett, E. D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051338 · Cited by 23

Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome

Giacomini, A., Stagni, F., Emili, M., Guidi, S., Salvalai, M. E., Grilli, M., Vidal, V., Martínez‐Cué, C., & Bartesaghi, R. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.06.009 · Cited by 19

Clinicopathological Staging of Dynamics of Neurodegeneration and Neuronal Loss in Alzheimer Disease

Węgiel, J., Flory, M. J., Kuchna, I., Nowicki, K., Ma, S. Y., Wegiel, J., Badmajew, E., de Leon, M. J., Wısnıewskı, T., & Reisberg, ‌. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa140 · Cited by 20

Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome

Caraci, F., Iulita, M. F., Pentz, R., Flores Aguilar, L., Orciani, C., Barone, C., Romano, C., Drago, F., & Cuello, A. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.004 · Cited by 18

Trends of Protein Aggregation in Neurodegenerative Diseases

Aǵbaş, A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81224 · Cited by 18

Genetic Susceptibility to Periodontal Disease in Down Syndrome: A Case-Control Study

Fernández, M., de Coo, A., Quintela, I., García, E. V., Freitas, M. D., Posse, J. L., Dios, P. D., Blanco, J., Carracedo, Á., & Cruz, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126274 · Cited by 18

Diagnosis and treatment of late-onset myoclonic epilepsy in Down syndrome (LOMEDS): A systematic review with individual patients’ data analysis

Corniello, C., Dono, F., Evangelista, G., Consoli, S., Angelis, S. D., Cipollone, S., Liviello, D., Polito, G., Melchiorre, S., Russo, M., et al. (2023) · Seizure · doi:10.1016/j.seizure.2023.05.017 · Cited by 21

Minding the Gap: Exploring Neuroinflammatory and Microglial Sex Differences in Alzheimer’s Disease

Reed-Geaghan, E. G., & Keller-Norrell, P. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417377 · Cited by 19

Alzheimer's disease research in the context of the national plan to address Alzheimer's disease

Snyder, H. M., Hendrix, J. A., Bain, L. J., & Carrillo, M. C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.06.005 · Cited by 18

Adiponectin Modulation by Genotype and Maternal Choline Supplementation in a Mouse Model of Down Syndrome and Alzheimer’s Disease

Alldred, M. J., Lee, S. H., & Ginsberg, S. D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132994 · Cited by 14

Cell models for Down syndrome-Alzheimer’s disease research

Wu, Y., West, N. R., Bhattacharyya, A., & Wiseman, F. K. (2022) · Neuronal Signaling · doi:10.1042/ns20210054 · Cited by 17

A Snapshot on the Current Status of Alzheimer’s Disease, Treatment Perspectives, in-Vitro and in-Vivo Research Studies and Future Opportunities

Tezel, G., Timur, S. S., Bozkurt, İ., Türkoğlu, Ö. F., Eroğlu, İ., Nemutlu, E., Öner, L., & Eroğlu, H. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00511 · Cited by 17

The Role of Oxidative Stress in Trisomy 21 Phenotype

Buczyńska, A., Sidorkiewicz, I., Kretowski, A. J., & Zbucka-Krętowska, M. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01417-6 · Cited by 21

People with intellectual disabilities at the end of their lives: The case for specialist care?

Forrester‐Jones, R., Beecham, J. K., Barnoux, M. F. L., Oliver, D., Couch, E., & Bates, C. (2017) · Journal of Applied Research in Intellectual Disabilities · doi:10.1111/jar.12412 · Cited by 16

Comparison of the amyloid plaque proteome in Down syndrome, early‐onset Alzheimer's disease, and late‐onset Alzheimer's disease

Martá-Ariza, M., Leitner, D. F., Kanshin, E., Suazo, J., Giusti Pedrosa, A., Thierry, M., Lee, E. B., Devinsky, O., Drummond, E., Fortea, J., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02844-z · Cited by 15

Aging and aging-associated diseases: a microRNA-based endocrine regulation hypothesis

Umansky, S. R. (2018) · Aging · doi:10.18632/aging.101612 · Cited by 16

Beyond Trisomy 21: Phenotypic Variability in People with Down Syndrome Explained by Further Chromosome Mis-segregation and Mosaic Aneuploidy

Potter, H. (2016) · Journal of Down Syndrome & Chromosome Abnormalities · doi:10.4172/2472-1115.1000109 · Cited by 16

Prevalence of congenital heart defects in people with Down syndrome: a systematic review and meta-analysis

Xu, C.-X., Chen, L., Cheng, Y., & Du, Y. (2025) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2023-220638 · Cited by 14

The association of increased body mass index on cardiorespiratory fitness, physical activity, and cognition in adults with down syndrome

Dodd, D., Helsel, B. C., Bodde, A. E., Danon, J. C., Sherman, J. R., Donnelly, J. E., Washburn, R. A., & Ptomey, L. T. (2023) · Disability and health journal · doi:10.1016/j.dhjo.2023.101497 · Cited by 18

From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach

Sukreet, S., Rafii, M. S., & Rissman, R. A. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12580 · Cited by 13

Humanin gene expression in fibroblast of Down syndrome subjects

Salemi, M., Ridolfo, F., Salluzzo, M. G., Cannarrella, R., Giambirtone, M., Caniglia, S., Tirolo, C., Ferri, R., & Romano, C. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.39145 · Cited by 14

Psychosocial Risk Factors for Alzheimer’s Disease in Patients with Down Syndrome and Their Association with Brain Changes: A Narrative Review

Hamadelseed, O., Elkhidir, I., & Skutella, T. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00361-9 · Cited by 16

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early‐onset Alzheimer's disease

Dekker, A. D., Vermeiren, Y., Carmona‐Iragui, M., Benejam, B., Videla, L., Gelpí, E., Aerts, T., Dam, D. V., Fernández, S., Lleó, A., et al. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.11.001 · Cited by 15

Untangle the mystery behind DS-associated AD – Is APP the main protagonist?

Elangovan, A., Babu, H. W. S., Iyer, M., Gopalakrishnan, A. V., & Vellingiri, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101930 · Cited by 12

The history of Down syndrome–associated Alzheimer's disease; past, present, and future

Maure‐Blesa, L., Carmona‐Iragui, M., Lott, I. T., Head, E., Wısnıewskı, T., Rafii, M. S., Espinosa, J. M., Flórez, J., Mobley, W. C., Holland, A. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70158 · Cited by 12

Deciphering the links between psychological stress, depression, and neurocognitive decline in patients with Down syndrome

Poumeaud, F., Mircher, C., Smith, P. J. K., Faye, P.-A., & Sturtz, F. G. (2021) · Neurobiology of Stress · doi:10.1016/j.ynstr.2021.100305 · Cited by 11

Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts

Mousa, Y. M., Abdallah, I. M., Hwang, M., Martin, D. R., & Kaddoumi, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-60664-5 · Cited by 11

A scoping review to characterize bridging tasks in the literature on aging with disability

Nalder, E. J., Saumur, T. M., Batliwalla, Z., Salvador‐Carulla, L., Putnam, M., Spindel, A., Lenton, E., & Hussein, H. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-5046-5 · Cited by 11

Case report: Ketogenic diet acutely improves cognitive function in patient with Down syndrome and Alzheimer’s disease

Bosworth, A., Loh, V., Stranahan, B. N., & Palmer, C. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1085512 · Cited by 14

Left ventricle diastolic function and cognitive performance in adults with Down syndrome

Vetrano, D. L., Carfì, A., Brandi, V., L’Angiocola, P. D., Tella, S. D., Cipriani, M. C., Antocicco, M., Zuccalà, G., Palmieri, V., Silveri, M. C., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.11.041 · Cited by 11

Anti-Amyloid-β Immunotherapy for Alzheimer’s Disease

Crehan, H., & Lemere, C. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00007-1 · Cited by 14

Critical role of mitosis in spontaneous late-onset Alzheimer’s disease; from a Shugoshin 1 cohesinopathy mouse model

Rao, C. V., Farooqui, M., Asch, A. S., & Yamada, H. Y. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1515554 · Cited by 11

The Central Role of Etiology in Science and Practice in Intellectual Disability

(2016) · International review of research in developmental disabilities · doi:10.1016/bs.irrdd.2016.05.005 · Cited by 13

Hippocampal CA1 Pyramidal Neurons Display Sublayer and Circuitry Dependent Degenerative Expression Profiles in Aged Female Down Syndrome Mice

Alldred, M. J., Pidikiti, H., Ibrahim, K. W., Lee, S. H., Heguy, A., Hoffman, G. E., Mufson, E. J., Stutzmann, G. E., & Ginsberg, S. D. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240622 · Cited by 10

Complexity Analysis of the Default Mode Network Using Resting-State fMRI in Down Syndrome: Relationships Highlighted by a Neuropsychological Assessment

Figueroa-Jiménez, M. D., Carbó‐Carreté, M., Cañete‐Massé, C., Zarabozo‐Hurtado, D., Peró, M., Estrada, J. G. S., & Guàrdia‐Olmos, J. (2021) · Brain Sciences · doi:10.3390/brainsci11030311 · Cited by 12

Nutraceutical and Probiotic Approaches to Examine Molecular Interactions of the Amyloid Precursor Protein APP in Drosophila Models of Alzheimer’s Disease

Jalali, D., Guevarra, J. A., Martinez, L., Hung, L., & Vonhoff, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137022 · Cited by 11

Involvement of an Aberrant Vascular System in Neurodevelopmental, Neuropsychiatric, and Neuro-Degenerative Diseases

Ishihara, K., Takata, K., & Mizutani, K. (2023) · Life · doi:10.3390/life13010221 · Cited by 10

‘I will never be old’: adults with Down syndrome and their parents talk about ageing-related challenges

Finkelstein, A., Tenenbaum, A., & Bachner, Y. G. (2019) · Ageing and Society · doi:10.1017/s0144686x19000266 · Cited by 10

Proteomic analysis of six- and twelve-month hippocampus and cerebellum in a murine Down syndrome model

Vacano, G. N., Gibson, D. S., Turjoman, A. A., Gawryluk, J. W., Geiger, J. D., Duncan, M. W., & Patterson, D. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.11.010 · Cited by 10

Integrated analysis of immunometabolic interactions in Down syndrome

Gillenwater, L. A., Galbraith, M. D., Rachubinski, A. L., Eduthan, N. P., Sullivan, K. D., Espinosa, J. M., & Costello, J. C. (2024) · Science Advances · doi:10.1126/sciadv.adq3073 · Cited by 9

Successful (and Unsuccessful) Recruitment Approaches and Participant Loss in a Down Syndrome Survey

Shaffer, M., Co, J. P. T., Donelan, K., Skotko, B. G., Torres, A., Winickoff, J. P., & Santoro, S. L. (2025) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-130.2.131 · Cited by 9

Neuropathological findings in Down syndrome, Alzheimer’s disease and control patients with and without SARS-COV-2: preliminary findings

Granholm, A., Englund, E. M., Gilmore, A., Head, E., Yong, W. H., Perez, S. E., Guzman, S. J., Hamlett, E. D., & Mufson, E. J. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02743-9 · Cited by 11

Alterations in the Serotonin and Dopamine Pathways by Cystathionine Beta Synthase Overexpression in Murine Brain

London, J., Ndiaye, F. K., Bui, L. C., Souchet, B., Daubigney, F., Magnan, C., Luquet, S. H., Dairou, J., Janel, N., & Rouch, C. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1323-2 · Cited by 9

Age-Group Differences in Body Mass Index, Weight, and Height in Adults With Down Syndrome and Adults With Intellectual Disability From the United States

Agiovlasitis, S., Jin, J., & Yun, J. (2021) · Adapted Physical Activity Quarterly · doi:10.1123/apaq.2020-0004 · Cited by 7

Development of a symptom menu to facilitate Goal Attainment Scaling in adults with Down syndrome-associated Alzheimer’s disease: a qualitative study to identify meaningful symptoms

Knox, K., Stanley, J., Hendrix, J. A., Hillerstrom, H., Dunn, T., Achenbach, J., Chicoine, B. A., Lai, F., Lott, I. T., Stanojevic, S., et al. (2021) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-020-00278-7 · Cited by 9

A Novel Framework to Measure Executive Function in Down Syndrome With Applications for Early Clinical Diagnosis of Dementia

Smith, E., Hedge, C., & Jarrold, C. (2019) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-124.4.354 · Cited by 9

Neuronal Cell-Intrinsic Defects in Mouse Models of Down Syndrome

Chiotto, A. M. A., Migliorero, M., Pallavicini, G., Bianchi, F. T., Gai, M., Di Cunto, F., & Berto, G. E. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01081 · Cited by 9

Serotonin and development

Whitaker‐Azmitia, P. M. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00023-2 · Cited by 9

Maternal choline supplementation rescues early endosome pathology in basal forebrain cholinergic neurons in the Ts65Dn mouse model of Down syndrome and Alzheimer’s disease

Gautier, M. K., Kelley, C. M., Lee, S. H., Mufson, E. J., & Ginsberg, S. D. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.09.002 · Cited by 8

Kynurenine pathway metabolite alterations in Down syndrome and Alzheimer's disease

dos Reis, R. G., Singulani, M. P., Forlenza, O. V., Gattaz, W. F., & Talib, L. L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70197 · Cited by 8

Toward the Identification of Neurophysiological Biomarkers for Alzheimer’s Disease in Down Syndrome: A Potential Role for Cross-Frequency Phase-Amplitude Coupling Analysis

Victorino, D. B., Faber, J., Pinheiro, D. J. L. L., Scorza, F. A., de Almeida, A.-C. G., Costa, A. C. S., & Scorza, C. A. (2022) · Aging and Disease · doi:10.14336/ad.2022.0906 · Cited by 8

Correlating MRI‐based brain volumetry and cognitive assessment in people with Down syndrome

Hamadelseed, O., & Skutella, T. (2023) · Brain and Behavior · doi:10.1002/brb3.3186 · Cited by 8

Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model

Araya, P., Niemeyer, B., Schade, K., Dunn, L. N., Waugh, K., Busquet, N., Brindley, C., Brown, C., Winkler, C., Lyford, H. R., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113130 · Cited by 7

Informant-based assessment instruments for dementia and their measurement properties in persons with intellectual disability: systematic review protocol

Zeilinger, E. L., Komenda-Schned, S., Novaković, I. Z., Franken, F., & Woditschka, K. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040920 · Cited by 7

Imaging of Tauopathies with PET Ligands: State of the Art and Future Outlook

Conte, M., Feo, M. S. D., Sidrak, M. M. A., Corica, F., Gorica, J., Granese, G. M., Filippi, L., Vincentis, G. D., & Frantellizzi, V. (2023) · Diagnostics · doi:10.3390/diagnostics13101682 · Cited by 8

Down syndrome and Alzheimer's disease: A scoping review of functional performance and fall risk

Washington, S. E., Cler, E., Lowery, C., & Stark, S. L. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12393 · Cited by 7

Investigating brain alterations in the Dp1Tyb mouse model of Down syndrome

Navacerrada, M. E. S., Kim, E., Siow, B. M., Ma, D., Gonzalez, L. R., Simmons, C., Hayward, D., Gibbins, D., Singh, N., Strydom, A., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106336 · Cited by 7

Alzheimer’s Disease-related Biomarkers in Aging Adults with Down Syndrome: Systematic Review

Bram, J. M. D. F., Talib, L. L., Joaquim, H. P. G., Carvalho, C. L., Gattaz, W. F., & Forlenza, O. V. (2019) · Current Psychiatry Research and Reviews · doi:10.2174/1573400515666190122152855 · Cited by 7

N-Acetylcysteine prevents amyloid-β secretion in neurons derived from human pluripotent stem cells with trisomy 21

Toshikawa, H., Ikenaka, A., Li, L., Nishinaka‐Arai, Y., Niwa, A., Ashida, A., Kazuki, Y., Nakahata, T., Tamai, H., Russell, D. W., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-96697-7 · Cited by 7

Editorial: Down Syndrome, Neurodegeneration and Dementia

Mufson, E. J., Ginsberg, S. D., Ma, T., Ledreux, A., & Perez, S. E. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.791044 · Cited by 7

Low TGF-β1 plasma levels are associated with cognitive decline in Down syndrome

Grasso, M., Fidilio, A., L’Episcopo, F., Recupero, M., Barone, C., Bacalini, M. G., Benatti, C., Giambirtone, M., Caruso, G., Greco, D., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1379965 · Cited by 7

Modified cued recall test in the French population with Down syndrome: A retrospective medical records analysis

Sacco, S., Falquero, S., Bouis, C., Akkaya, M., Gallard, J., Pichot, A., Radice, G., Bazin, F., Montestruc, F., Hiance‐Delahaye, A., et al. (2022) · Journal of Intellectual Disability Research · doi:10.1111/jir.12957 · Cited by 6

Gut dysbiosis and neurological modalities: An engineering approach via proteomic analysis of gut-brain axis

Kandpal, M., Varshney, N., Rawal, K. S., & Jha, H. C. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.02.001 · Cited by 6

Vital Role of Monoamine Oxidases and Cholinesterases in Central Nervous System Drug Research: A Sharp Dissection of the Pathophysiology

Aksöz, B. E., & Aksöz, E. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666200220115154 · Cited by 6

Trisomy 21 impairs PGE2 production in dermal fibroblasts

Marentette, J., Anderson, C. C., Prutton, K. M., Jennings, E. Q., Rauniyar, A. K., Galligan, J. J., & Roede, J. R. (2021) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2020.106524 · Cited by 8

Long-term bumetanide administration altered behavioral pattern in mosaic Down’s Syndrome: A case report

Gharaylou, Z., Shafaghi, L., Pestehei, S. K., & Hadjighassem, M. (2021) · Applied Neuropsychology Child · doi:10.1080/21622965.2021.2007481 · Cited by 6

Iron Responsiveness to Lysosomal Disruption: A Novel Pathway to Alzheimer’s Disease

Rogers, J. T., & Cahill, C. M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230953 · Cited by 6

Current insights and prospects for the pathogenesis and treatment of clinical manifestations associated with Down syndrome through neurotransmitter, inflammatory, and oxidative stress pathways

Alasmari, F. F., Ahmad, A., Alsanea, S., Hammad, A. M., & Al-Qerem, W. A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1592277 · Cited by 8

Influence of Physical Activity Interventions on Executive Functions for Down Syndrome: A Systematic Review

Scott, N. M., Schmid, D. G., Tomporowski, P. D., & Kirk, T. N. (2025) · Adapted Physical Activity Quarterly · doi:10.1123/apaq.2024-0107 · Cited by 6

Tiny Toes to Tau Tangles: Down's Syndrome and Its Association With Alzheimer's Disease

Puttagunta, S. M., Islam, R., Kundu, S., Jha, S. B., Rivera, A. P., Monar, G. V. F., Islam, H., & Sange, I. (2022) · Cureus · doi:10.7759/cureus.22125 · Cited by 6

Increases of SET level and translocation are correlated with tau hyperphosphorylation at ser202/thr205 in CA1 of Ts65Dn mice

Dorard, E., Gorisse-Hussonnois, L., Guihenneuc‐Jouyaux, C., Albac, C., Potier, M., & Allinquant, B. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.06.010 · Cited by 5

Increased choroidal thickness in adults with Down syndrome

Csincsik, L., Nelson, R., Walpert, M., Pető, T., Holland, A. J., & Lengyel, I. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12170 · Cited by 4

Novel immunological approaches for the treatment of Alzheimer's disease.

Sabharwal, P., & Wısnıewskı, T. (2014) · PubMed · doi:10.3969/j.issn.1672-6731.2014.03.001 · Cited by 5

Aging with Intellectual Disability: Dementia and Cognitive Decline

Sheerin, F. K., McCallion, P., McGlinchey, E., O’Dwyer, M., Reilly, E., & McCarron, M. (2020) · Autism and child psychopathology series · doi:10.1007/978-3-030-46835-4_19 · Cited by 5

Vitamin D3 increases the Caspase-3 p12, MTHFR, and P-glycoprotein reducing amyloid-β42 in the kidney of a mouse model for Down syndrome

Gomes, F. D. C., Neto, J. S. D. M., Ferrari, M. D. F. R., Carlos, C. P., Goloni‐Bertollo, E. M., & Pavarino, É. C. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.06.012 · Cited by 5

Pro-inflammatory Cytokine GM-CSF Improves Learning/Memory and Brain Pathology in Dp16 Down Syndrome Mice and Improves Learning/Memory in Wild-Type MicePreprint

Ahmed, M. M., Wang, A. C.-J., Elos, M. T., Chial, H. J., Sillau, S. H., Solano, D., Coughlan, C. M., Aghili, L., Anton, P., Markham, N., et al. (2021) · bioRxiv · doi:10.1101/2021.07.04.451073 · Cited by 2

Transcriptomic analysis of stem cells from chorionic villi uncovers the impact of chromosomes 2, 6 and 22 in the clinical manifestations of Down syndrome

Vaiasicca, S., Melone, G., James, D. W., Quintela, M., Preziuso, A., Finnell, R. H., Conlan, R. S., Francis, L. W., & Corradetti, B. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03503-4 · Cited by 4

Altered pro-inflammatory and anti-inflammatory plasma cytokines levels in children with Down’s syndrome

Nigam, N., Singh, P. K., Raizada, N., Singh, B., Tripathi, S., Agrawal, M., Gupta, H., Singh, S. K., Fatima, G., Nigam, S. K., et al. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_364_21 · Cited by 4

Copy Number Variants: Deletion and Duplication Syndromes

Harner, M. K., Bishop, D. V., Pollak, R. M., Purcell, R. H., & Mullé, J. G. (2025) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-121222-120601 · Cited by 4

White matter microstructure in school-age children with down syndrome

Garic, D., Al‐Ali, K., Nasir, A., Azrak, O., Grzadzinski, R., McKinstry, R. C., Wolff, J. J., Lee, C.-M., Pandey, J., Schultz, R. T., et al. (2025) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2025.101540 · Cited by 4

Further understanding the connection between Alzheimer's disease and Down syndrome

Snyder, H. M., Bain, L. J., Brickman, A. M., Carrillo, M. C., Esbensen, A. J., Espinosa, J. M., Fernandez, F., Fortea, J., Hartley, S. L., Head, E., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12112 · Cited by 105

Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology

Rafii, M. S., Schlachetzki, Z., Barroeta, I., Head, E., Fortea, J., & Ances, B. M. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00237-6 · Cited by 44

Down's syndrome and Alzheimer's disease

Mann, D. M. A. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511526886.011 · Cited by 2

Relationship of Down’s Syndrome to Alzheimer’s Disease

Rabe, A., Wisniewski, K. E., Schupf, N., & Wı́sniewski, H. M. (1990) · Springer eBooks · doi:10.1007/978-1-4613-0525-5_21 · Cited by 19

Alzheimer’s disease and Down syndrome

Pelt, K. L. V., Head, E., Schmitt, F. A., & Koehl, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00020-9 · Cited by 5